Compounds > perfosfamide
Page last updated: 2024-08-23

perfosfamide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

perfosfamide has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andersson, BS; Britten, RA; Farquhar, D; Mroue, M; Murray, D1
Andersson, BS; Britten, RA; Mroue, M; Murray, D1
Rosenfeld, CS1
Kim, BK; Kim, NK; Lee, JH; Lee, JT; Park, S1
Eaves, AC; Eaves, CJ; Lansdorp, PM; Udomsakdi, C1
Ballard, K; Jollow, DJ; Oatis, JE; Peters, RH; Stuart, RK1

Other Studies

6 other study(ies) available for perfosfamide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line.
    Acta oncologica (Stockholm, Sweden), 1995, Volume: 34, Issue:2

    Topics: Aldehyde Dehydrogenase; Cell Survival; Cyclophosphamide; Drug Resistance, Multiple; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoramide Mustards; Radiation Dosage; Tumor Cells, Cultured

1995
The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues.
    Cancer research, 1994, Oct-15, Volume: 54, Issue:20

    Topics: Aldehyde Dehydrogenase; Cyclophosphamide; DNA Damage; DNA Repair; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoramide Mustards; Tumor Cells, Cultured

1994
Antileukemic activity of phenylalanine methyl ester (PME): a lysosomotropic peptide methyl ester.
    Stem cells (Dayton, Ohio), 1994, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Child; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monocytes; Phenylalanine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temperature; Tumor Cells, Cultured

1994
Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.
    Journal of Korean medical science, 1996, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Cyclophosphamide; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured

1996
Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia.
    Blood, 1992, Nov-15, Volume: 80, Issue:10

    Topics: Antigens, CD; Antigens, CD34; Cell Division; Clone Cells; Cyclophosphamide; Fluorescent Dyes; Hematopoietic Stem Cells; HLA-DR Antigens; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Light; Phenotype; Rhodamine 123; Rhodamines; Scattering, Radiation

1992
Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26, Issue:6

    Topics: Antimetabolites; Buthionine Sulfoximine; Cell Line; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Interactions; Glutathione; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methionine Sulfoximine; Sulfhydryl Compounds; Tumor Cells, Cultured

1990